136 related articles for article (PubMed ID: 25477715)
1. Maternal plasma and amniotic fluid chemokines screening in fetal Down syndrome.
Laudanski P; Zbucka-Kretowska M; Charkiewicz K; Wolczynski S; Wojcik D; Charkiewicz R
Mediators Inflamm; 2014; 2014():835837. PubMed ID: 25477715
[TBL] [Abstract][Full Text] [Related]
2. Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome.
Charkiewicz K; Zbucka-Kretowska M; Goscik J; Wolczynski S; Lemancewicz A; Laudanski P
J Immunol Res; 2016; 2016():9362169. PubMed ID: 27042674
[TBL] [Abstract][Full Text] [Related]
3. Maternal plasma and amniotic fluid sphingolipids profiling in fetal Down syndrome.
Charkiewicz K; Blachnio-Zabielska A; Zbucka-Kretowska M; Wolczynski S; Laudanski P
PLoS One; 2015; 10(5):e0127732. PubMed ID: 26000716
[TBL] [Abstract][Full Text] [Related]
4. Amniotic fluid NF-kB concentration in pregnant women with a high risk of prenatal screening test results.
Arpacı H; Yapca OE
Ginekol Pol; 2018; 89(10):577-580. PubMed ID: 30393848
[TBL] [Abstract][Full Text] [Related]
5. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
[TBL] [Abstract][Full Text] [Related]
6. Amniotic Fluid Angiogenic and Inflammatory Factor Profiling in Foetal Down Syndrome.
Zbucka-Kretowska M; Charkiewicz K; Czerniecki J; Goscik J; Wolczynski S; Laudanski P
Fetal Diagn Ther; 2018; 44(1):44-50. PubMed ID: 28715807
[TBL] [Abstract][Full Text] [Related]
7. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome.
Perrone S; Longini M; Bellieni CV; Centini G; Kenanidis A; De Marco L; Petraglia F; Buonocore G
Clin Biochem; 2007 Feb; 40(3-4):177-80. PubMed ID: 17208212
[TBL] [Abstract][Full Text] [Related]
8. Occult inflammation and/or ischemia may be responsible for the false positivity of biochemical Down syndrome screening test.
Guven S; Karahan SC; Kandemir O; Ucar U; Cora AO; Bozkaya H
J Perinat Med; 2010 Jul; 38(4):367-71. PubMed ID: 20297899
[TBL] [Abstract][Full Text] [Related]
9. Human placental growth hormone is increased in maternal serum in pregnancies affected by Down syndrome.
Papadopoulou E; Sifakis S; Giahnakis E; Fragouli Y; Karkavitsas N; Koumantakis E; Kalmanti M
Fetal Diagn Ther; 2008; 23(3):211-6. PubMed ID: 18417980
[TBL] [Abstract][Full Text] [Related]
10. [Maternal serum screening for Down syndrome and neural tube defects].
van Rijn M; Christiaens GC; van der Schouw YT; Hagenaars AM; de Pater JM; Visser GH
Ned Tijdschr Geneeskd; 1998 Feb; 142(8):409-15. PubMed ID: 9562776
[TBL] [Abstract][Full Text] [Related]
11. AFP and age screening for Down syndrome.
Wald N; Cuckle H
Am J Med Genet; 1988 Sep; 31(1):197-209. PubMed ID: 2464930
[TBL] [Abstract][Full Text] [Related]
12. Are amniotic fluid C-reactive protein and glucose levels, and white blood cell counts at the time of genetic amniocentesis related with preterm delivery?
Tarim E; Bağiş T; Kiliçdağ EB; Sezgin N; Yanik F
J Perinat Med; 2005; 33(6):524-9. PubMed ID: 16318616
[TBL] [Abstract][Full Text] [Related]
13. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
Dick PT
CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of amino acids in plasma and amniotic fluid of women from genetic risk groups].
Duczyńska N; Cabalska B; Nowaczewska I; Mazurczak T; Klawe H
Probl Med Wieku Rozwoj; 1990; 16():103-15. PubMed ID: 2152396
[TBL] [Abstract][Full Text] [Related]
15. Monocyte chemotactic protein-1 is increased in the amniotic fluid of women who deliver preterm in the presence or absence of intra-amniotic infection.
Esplin MS; Romero R; Chaiworapongsa T; Kim YM; Edwin S; Gomez R; Mazor M; Adashi EY
J Matern Fetal Neonatal Med; 2005 Jun; 17(6):365-73. PubMed ID: 16009638
[TBL] [Abstract][Full Text] [Related]
16. Human chromosome 21-specific DNA markers are useful in prenatal detection of Down syndrome.
Liou JD; Chu DC; Cheng PJ; Chang SD; Sun CF; Wu YC; Liou WY; Chiu DT
Ann Clin Lab Sci; 2004; 34(3):319-23. PubMed ID: 15487707
[TBL] [Abstract][Full Text] [Related]
17. Maternal plasma levels of follistatin-related gene protein in the first trimester of pregnancies with Down syndrome.
Miron P; Lambert J; Marcil A; Cowans NJ; Stamatopoulou A; Spencer K
Prenat Diagn; 2010 Mar; 30(3):224-8. PubMed ID: 20063262
[TBL] [Abstract][Full Text] [Related]
18. Fetal cell-free nucleic acids in the maternal circulation: new clinical applications.
Wataganara T; Bianchi DW
Ann N Y Acad Sci; 2004 Jun; 1022():90-9. PubMed ID: 15251945
[TBL] [Abstract][Full Text] [Related]
19. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia.
Park CW; Park JS; Shim SS; Jun JK; Yoon BH; Romero R
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):984-9. PubMed ID: 16157098
[TBL] [Abstract][Full Text] [Related]
20. Elevated second trimester amniotic fluid interferon gamma-inducible T-cell alpha chemoattractant concentrations as a possible predictor of preterm birth.
Malamitsi-Puchner A; Vrachnis N; Samoli E; Baka S; Hassiakos D; Creatsas G
J Soc Gynecol Investig; 2006 Jan; 13(1):25-9. PubMed ID: 16378910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
